{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
alpha-tocopherol acetate
to a specific field?
Status:
Investigational
Source:
J Zoo Wildl Med. Sep 2016;47(3):834-843.: Not Applicable Veterinary clinical trial Completed N/A
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Etorphine was the first potent opiate agonist employed primarily for use in non-domestic and wild species. Etorphine was 500 times as potent as morphine, with a very rapid onset and short duration of action. In morphine-dependent subjects, etorphine suppressed abstinence but for a shorter period than morphine. Etorphine is a full opiate agonist and binds to multiple opiate sites in the central nervous system. It is believed to produce its clinical effects through binding the µ-, δ-, and κ- opiate sites. It has a potent effect on depressing the respiratory centers of the CNS thus resulting in apnea being commonly seen in immobilized animals. Etorphine revolutionized the ability of biologists and veterinarians to safely capture and restrain many species that previously could not be handled. Etorphine is not currently commercially available due to lack of production by the manufacturer.
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Fedotozine [(1R)-1-phenyl-1-[(3,4,5-trimethoxy) benzyloxymethyl]-N,N- dimethyl-n-propylamine, (2S,3S-tartrate], derived from the arylacetamide series, is an opioid drug which acts as a selective agonist for kappa(1a)-opioid receptor. Pharmacological studies have shown that fedotozine exerts a peripheral antinociceptive action, comparable with that of other kappa-agonists. Results of Phase III trials of fedotozine against irritable bowel syndrome and dyspepsia have ultimately been disappointing and was lack of efficacy in subsequent studies.
Class (Stereo):
CHEMICAL (RACEMIC)
Moxipraquine is alkylaminopiperazinyl derivative patented by Wellcome Foundation Ltd. as antiparasitic agent effective against Trypanosoma cruzi. Moxipraquine was effective in suppressing parasitaemia but did not eradicate the infection from mice or guinea-pigs. Moxipraquine was less potent against mouse infections with strain Peru than it was against other strains of T. cruzi. In limited tests, moxipraquine was effective on experimental infections of Leishmania major, L. mexicana mexicana and L. brasiliensis panamensis but not L.b. brasiliensis. Significant foetal toxicity, observed experimentally in rats and rabbits, resulted in the termination of further trials.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Hydromorphinol, an opioid, and is a derivative of morphine and possesses similar properties: sedation, analgesia, and respiratory depression. Hydromorphinol is under the control according to US Single Convention 1961.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Proclonol is a cyclopropylmethanol derivative patented by Belgium pharmaceutical company Janssen Pharmaceutica N. V. as an arachnicide and fungicide. Tetranychus urticae in the adult stage on bean plants were killed within 3 days with a spray contg. 35 ppm. Proclonol, while all of the larval stage on strawberry leaves was killed by 62.5 ppm., and no eggs sprayed with 40 ppm. hatched. A suspension of 500 ppm. Proclonol used to dip strawberry leaves infested with Tarsonemus pallidus killed 96.2% of the mites.
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
FENYRIPOL is a skeletal muscle relaxant.
Status:
Investigational
Source:
NCT00495885: Phase 3 Interventional Completed Sleep Initiation and Maintenance Disorders
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Volinanserin (MDL-100,907) is a highly selective 5-HT2A receptor antagonist. It is widely used in
scientific research to investigate the function of the 5-HT2A receptor. Volinanserin is also being trialed as a
potential antipsychotic, antidepressant and treatment for insomnia. Volinanserin (M-100907) was in
phase III trials for chronic schizophrenia. In August 1999, development was discontinued for acute
schizophrenia (schizoaffective disorder) on the basis of poor results. M-100907 is also active in animal
models involving blockade of NMDA glutamatergic channel receptors, an effect known to resemble some
behavioral symptoms of schizophrenia in man. M-100907 is also claimed in other patents for the
treatment of thromboembolic disorders, for the treatment of various developmental neurological
disorders such as autism and attention deficit hyperactivity disorder.
Status:
Investigational
Source:
INN:desocriptine [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Desocriptine is an ergot alkaloid (alpha-dihydro-beta-ergocryptine) derivative. It is a combined alpha- and beta-adrenoceptor antagonist. Desocriptine is antihypertensive and antianginal agent.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Minaxolone, a water-soluble steroid anesthetic that was studied in 1970s/1980s. It is a positive allosteric modulator of the GABAA receptor. This compound was withdrawn before registration due to reported toxicity in rats.
Status:
Investigational
Source:
NCT04374032: Phase 2/Phase 3 Interventional Completed COVID-19 Infection
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Metenkephalin (Met-enkephalin) is an endogenous opioid peptide that acts as an agonist at μ-opioid receptors (μORs) and δ-opioid receptors (δORs). Met-enkephalin exhibits neuromodulatory, antinociceptive/analgesic, antidepressant, and gastrointestinal motility modulating activities. Like other endogenous opioids, met-enkephalin modulates expression of opioid receptors and plays a role in reward/reinforcement signaling. Met-enkephalin is also involved in exercise-induced reversal of neuropathic pain and in animals undergoing the forced swim test, decreases immobility time. Met-enkephalin inhibits gastrointestinal muscle contractility, inhibiting motility and gastric emptying. Additionally, analogs of this peptide display anticancer and antiepileptic/anticonvulsant activities.
